Last reviewed · How we verify
CartiLife
CartiLife is a regenerative medicine therapy designed to repair or regenerate cartilage tissue, likely through cell-based or tissue engineering approaches.
CartiLife is a regenerative medicine therapy designed to repair or regenerate cartilage tissue, likely through cell-based or tissue engineering approaches. Used for Cartilage defects or osteoarthritis (presumed, based on product name).
At a glance
| Generic name | CartiLife |
|---|---|
| Sponsor | Biosolution Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Regenerative Medicine |
| Phase | Phase 2 |
Mechanism of action
CartiLife appears to be a cartilage regeneration or restoration therapy in early clinical development. Given the name and phase 2 status, it likely involves cellular or biomaterial-based approaches to address cartilage defects or osteoarthritis. The exact mechanism—whether cell transplantation, scaffold-based regeneration, or growth factor delivery—is not publicly detailed.
Approved indications
- Cartilage defects or osteoarthritis (presumed, based on product name)
Common side effects
Key clinical trials
- Phase 2 Clinical Trial of CartiLife® in the United States (PHASE2)
- Phase 3 Clinical Trial of CartiLife® in Korea (PHASE3)
- Study to Assess the Efficacy and Safety of Treatment of Articular Cartilage Lesions With CartiLife® (PHASE2)
- Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |